EFFECT OF CONTROLLED ADVENTITIAL HEPARIN DELIVERY ON SMOOTH-MUSCLE CELL-PROLIFERATION FOLLOWING ENDOTHELIAL INJURY

被引:228
作者
EDELMAN, ER
ADAMS, DH
KARNOVSKY, MJ
机构
[1] BRIGHAM & WOMENS HOSP,DEPT INTERNAL MED,DIV CARDIOVASC,BOSTON,MA 02115
[2] BRIGHAM & WOMENS HOSP,DEPT SURG,BOSTON,MA 02115
[3] MIT,DEPT HLTH SCI & TECHNOL,CAMBRIDGE,MA 02139
关键词
angioplasty; Atherosclerosis; polymer-based controlled delivery; vascular injury; vascular surgery;
D O I
10.1073/pnas.87.10.3773
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Continuous intravenous infusion of heparin suppresses smooth muscle cell proliferation in rats after endothelial injury but may lead to hemorrhage and other complications. The anticoagulant property has been removed from chemically modified heparin without loss of antiproliferative effect but use of such compounds is still limited. In this study ethylene-vinyl acetate copolymer matrices containing standard and modified heparin were placed adjacent to rat carotid arteries at the time of balloon dendothelialization. After 14 days arterial occlusion by smooth muscle cell proliferation was defined. Matrix delivery of both heparin compounds effectively diminished this proliferation in comparison to controls without producing systemic anticoagulation or side effects. In addition, this mode of therapy appeared more effective than the administration of the same agents by either intravenous pumps or heparin/polymer matrices placed in a subcutaneous site distant from the injured carotid artery. Thus, heparin's inhibition for smooth muscle cell proliferation after vascular injury might be most effective within the microenvironment of the injured vessel wall, and the accelerated atherosclerosis or restenosis that often follows angioplasty and other vascular interventions might best be treated with site-specific therapy.
引用
收藏
页码:3773 / 3777
页数:5
相关论文
共 30 条
[1]   INTIMAL PROLIFERATION OF SMOOTH-MUSCLE CELLS AS AN EXPLANATION FOR RECURRENT CORONARY-ARTERY STENOSIS AFTER PERCUTANEOUS TRANS-LUMINAL CORONARY ANGIOPLASTY [J].
AUSTIN, GE ;
RATLIFF, NB ;
HOLLMAN, J ;
TABEI, S ;
PHILLIPS, DF .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1985, 6 (02) :369-375
[2]   CLINICAL USE OF INTRAPULMONARY HEPARIN [J].
BICK, RL ;
ROSS, ES .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1985, 11 (02) :213-217
[3]   CONTROLLED RELEASE OF INSULIN FROM POLYMER MATRICES - CONTROL OF DIABETES IN RATS [J].
BROWN, L ;
MUNOZ, C ;
SIEMER, L ;
EDELMAN, E ;
LANGER, R .
DIABETES, 1986, 35 (06) :692-697
[4]   INVIVO AND INVITRO RELEASE OF MACROMOLECULES FROM POLYMERIC DRUG DELIVERY SYSTEMS [J].
BROWN, LR ;
WEI, CL ;
LANGER, R .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1983, 72 (10) :1181-1185
[5]   REGULATION OF VASCULAR SMOOTH-MUSCLE CELL-GROWTH BY HEPARIN AND HEPARAN SULFATES [J].
CASTELLOT, JJ ;
WRIGHT, TC ;
KARNOVSKY, MJ .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1987, 13 (04) :489-503
[6]   STRUCTURAL DETERMINANTS OF THE CAPACITY OF HEPARIN TO INHIBIT THE PROLIFERATION OF VASCULAR SMOOTH-MUSCLE CELLS [J].
CASTELLOT, JJ ;
BEELER, DL ;
ROSENBERG, RD ;
KARNOVSKY, MJ .
JOURNAL OF CELLULAR PHYSIOLOGY, 1984, 120 (03) :315-320
[7]  
CLOWES AW, 1983, LAB INVEST, V49, P327
[8]   SUPPRESSION BY HEPARIN OF SMOOTH-MUSCLE CELL-PROLIFERATION IN INJURED ARTERIES [J].
CLOWES, AW ;
KARNOWSKY, MJ .
NATURE, 1977, 265 (5595) :625-626
[9]   ABSORPTION OF HEPARIN, LMW HEPARIN AND SP54 AFTER SUBCUTANEOUS INJECTION, ASSESSED BY COMPETITIVE-BINDING ASSAY [J].
DAWES, J ;
PROWSE, CV ;
PEPPER, DS .
THROMBOSIS RESEARCH, 1986, 44 (05) :683-693
[10]   RELATION BETWEEN ARTERIAL INTIMAL THICKENING AND THE VASA-VASORUM [J].
DIAZFLORES, L ;
DOMINGUEZ, C .
VIRCHOWS ARCHIV A-PATHOLOGICAL ANATOMY AND HISTOPATHOLOGY, 1985, 406 (02) :165-177